Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (221-230 of 339) with videos related to

Pageof 34
Sort By:
Leukemia Research|November 19, 2013
Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter studyJudith Neukirchen, Michael Lauseker, Sabine Blum, et al.
Leukemia Research|February 14, 2014
Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survivalLisa Pleyer, Ulrich Germing, Wolfgang R Sperr, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 18, 2018
Surveillance of Myelodysplastic Syndrome via Migration Analyses of Blood Neutrophils: A Potential Prognostic ToolMarc Schuster, Mischa Moeller, Lea Bornemann, et al.
American Journal of Hematology|March 2, 2017
Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patientsDevendra K Hiwase, Deepak Singhal, Corinna Strupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS StudyUwe Platzbecker, Katharina S Götze, Philipp Kiewe, et al.
Annals of Hematology|August 7, 2014
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studiesMargriet Oosterveld, Stefan Suciu, Petra Muus, et al.
Leukemia Research|January 30, 2007
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conferencePeter Valent, Hans-Peter Horny, John M Bennett, et al.
Frontiers in Oncology|July 16, 2024
Chronic myelomonocytic leukemia with ring sideroblasts/<i>SF3B1</i> mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/<i>SF3B1</i> mutation in terms of phenotype and prognosisBlanca Xicoy, Helena Pomares, Mireia Morgades, et al.
Leukemia|February 19, 2020
Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7Elena Crisà, Austin G Kulasekararaj, Vera Adema, et al.
Annals of Hematology|September 25, 2015
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)Heiko Becker, Stefan Suciu, Björn Hans Rüter, et al.
Pageof 34

Showing results (221-230 of 339) with videos related to

Sort By:
Pageof 34
Leukemia Research|November 19, 2013
Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter studyJudith Neukirchen, Michael Lauseker, Sabine Blum, et al.
Leukemia Research|February 14, 2014
Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survivalLisa Pleyer, Ulrich Germing, Wolfgang R Sperr, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 18, 2018
Surveillance of Myelodysplastic Syndrome via Migration Analyses of Blood Neutrophils: A Potential Prognostic ToolMarc Schuster, Mischa Moeller, Lea Bornemann, et al.
American Journal of Hematology|March 2, 2017
Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patientsDevendra K Hiwase, Deepak Singhal, Corinna Strupp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS StudyUwe Platzbecker, Katharina S Götze, Philipp Kiewe, et al.
Annals of Hematology|August 7, 2014
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studiesMargriet Oosterveld, Stefan Suciu, Petra Muus, et al.
Leukemia Research|January 30, 2007
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conferencePeter Valent, Hans-Peter Horny, John M Bennett, et al.
Frontiers in Oncology|July 16, 2024
Chronic myelomonocytic leukemia with ring sideroblasts/<i>SF3B1</i> mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/<i>SF3B1</i> mutation in terms of phenotype and prognosisBlanca Xicoy, Helena Pomares, Mireia Morgades, et al.
Leukemia|February 19, 2020
Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7Elena Crisà, Austin G Kulasekararaj, Vera Adema, et al.
Annals of Hematology|September 25, 2015
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)Heiko Becker, Stefan Suciu, Björn Hans Rüter, et al.
Pageof 34